Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 11/2022

Open Access 14-07-2022 | Radiotherapy | Original Article

Cost effectiveness and health-related quality of life of chemoradiotherapy versus radiation therapy alone in elderly head and neck cancer patients

Authors: Tanja Sprave, M.D., M.B.A., Vivek Verma, M.D., Alexander Fabian, M.D., M.B.A., Alexander Rühle, M.D., Dimos Baltas, Ph.D., Anca-Ligia Grosu, M.D., Nils H. Nicolay, M.D., Ph.D.

Published in: Strahlentherapie und Onkologie | Issue 11/2022

Login to get access

Abstract

Purpose

Radiotherapy (RT) constitutes a mainstay in the treatment of elderly patients with head and neck cancer (HNC), but use of simultaneous chemoradiotherapy (CRT) remains controversial. We have conducted a prospective analysis based on real-world patient data to examine the health-related quality of life (HRQoL) and cost effectiveness (CE) of CRT vs. RT in elderly HNC patients.

Methods

Eligible participants ≥ 65 years treated in a large tertiary cancer center between July 2019 and February 2020 who completed the validated EQ-5D-5L questionnaire (health state index [HI] and visual analog scale [VAS]) before and after RT were included. CE referred to direct medical costs, including diagnosis-related group (DRG)-based billings for inpatients and uniform assessment standard (EBM)-based costs for outpatients. The primary endpoint was cost (euros [€]) per quality-adjusted life year (QALY). The incremental cost-effectiveness ratios (ICERs) were calculated. Costs and QALYs were not discounted for short overall survival (OS).

Results

Baseline HRQoL was 0.878 (±0.11) in the CRT group and 0.857 (±0.17) in the RT group. Upon completion of therapy, HRQoL amounted to 0.849 (±0.14) in the CRT and 0.850 (±0.13) in the RT group. The mean treatment-related cost in the CRT cohort was €22,180.17 (±8325.26) vs. €18,027.87 (±26,022.48) in the RT group. The corresponding QALYs amounted to 2.62 in the CRT and 1.91 in the RT groups. The ICER was €5848.31.

Conclusion

This is the first analysis from the German health care system demonstrating that the addition of chemotherapy to RT for selected elderly HNC patients is cost effective and not associated with a significant HRQoL decline.
Literature
1.
Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA (2009) Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 27:2758–2765PubMedCrossRef
2.
Vahl JM, Wigand MC, Denkinger M, Dallmeier D, Steiger C, Welke C et al (2021) Increasing mean age of head and neck cancer patients at a German tertiary referral center. Cancers 13:832PubMedPubMedCentralCrossRef
3.
van den Bussche H, Kaduszkiewicz H, Schafer I, Koller D, Hansen H, Scherer M et al (2016) Overutilization of ambulatory medical care in the elderly German population?—An empirical study based on national insurance claims data and a review of foreign studies. BMC Health Serv Res 16:129PubMedPubMedCentralCrossRef
4.
Heinrich S, Luppa M, Matschinger H, Angermeyer MC, Riedel-Heller SG, Konig HH (2008) Service utilization and health-care costs in the advanced elderly. Value Health 11:611–620PubMedCrossRef
5.
Ebert N, Kensche A, Lock S, Hadiwikarta WW, Hansch A, Dorr W et al (2021) Results of a randomized controlled phase III trial: efficacy of polyphenol-containing cystus(R) tea mouthwash solution for the reduction of mucositis in head and neck cancer patients undergoing external beam radiotherapy. Strahlenther Onkol 197:63–73PubMedCrossRef
6.
Loser A, Ramke K, Grohmann M, Krause L, Roser P, Greinert F et al (2022) The impact of nutritional counseling on thyroid disorders in head and neck cancer patients after (chemo)radiotherapy: results from a prospective interventional trial. Strahlenther Onkol 198:135–148PubMedCrossRef
7.
Fleming I, Monaghan P, Gavin A, O’Neill C (2008) Factors influencing hospital costs of lung cancer patients in Northern Ireland. Eur J Health Econ 9:79–86PubMedCrossRef
8.
Sail KR, Franzini L, Lairson DR, Du XL (2012) Clinical and economic outcomes associated with adjuvant chemotherapy in elderly patients with early stage operable breast cancer. Value Health 15:72–80PubMedCrossRef
9.
Tribius S, Haladyn S, Hanken H, Busch CJ, Krull A, Petersen C et al (2021) Parotid sparing and quality of life in long-term survivors of locally advanced head and neck cancer after intensity-modulated radiation therapy. Strahlenther Onkol 197:219–230PubMedCrossRef
10.
11.
Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‑year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28PubMedCrossRef
12.
Derks W, de Leeuw JR, Hordijk GJ, Winnubst JA (2005) Reasons for non-standard treatment in elderly patients with advanced head and neck cancer. Eur Arch Otorhinolaryngol 262:21–26PubMedCrossRef
13.
Mayer A, Wenzel W, Wollschlager D, Bostel T, Kruger M, Matthias C et al (2022) Adjuvant chemoradiotherapy in elderly patients with head and neck cancer: a monoinstitutional, two-to-one pair-matching analysis. Strahlenther Onkol 198:159–170PubMedPubMedCentralCrossRef
14.
Bradley CJ, Dahman B, Anscher M (2014) Prostate cancer treatment and survival: evidence for men with prevalent comorbid conditions. Med Care 52:482–489PubMedPubMedCentralCrossRef
15.
Ruhle A, Haehl E, Kalckreuth T, Stoian R, Spohn SKB, Sprave T et al (2021) Surviving elderly patients with head-and-neck squamous cell carcinoma-what is the long-term quality of life after curative radiotherapy? Cancers (Basel) 13(6):1275CrossRef
16.
Barbieri M, Weatherly HL, Ara R, Basarir H, Sculpher M, Adams R et al (2014) What is the quality of economic evaluations of non-drug therapies? A systematic review and critical appraisal of economic evaluations of radiotherapy for cancer. Appl Health Econ Health Policy 12:497–510PubMedPubMedCentralCrossRef
17.
Medenwald D, Dietzel CT, Vordermark D (2018) Health services research in German radiation oncology: new opportunities to advance cancer care. Strahlenther Onkol 194:1097–1102PubMedCrossRef
18.
Tribius S, Meyer MS, Pflug C, Hanken H, Busch CJ, Krull A et al (2018) Socioeconomic status and quality of life in patients with locally advanced head and neck cancer. Strahlenther Onkol 194:737–749PubMedCrossRef
19.
Guigay J, Le Caer H, Ortholan C, Auperin A, Michel C, Mertens C (2019) Treatment of inoperable elderly head and neck cancer patients. Curr Opin Oncol 31:152–159PubMedCrossRef
20.
Guigay J, Mertens C, Le Caer H, Michel C, Ortholan C, Auperin A (2017) A French multicenter research program for a personalized treatment of elderly head and neck cancer patien. Bull Cancer 104:816–819PubMedCrossRef
21.
Devlin NJ, Parkin D, Browne J (2010) Patient-reported outcome measures in the NHS: new methods for analysing and reporting EQ-5D data. Health Econ 19:886–905PubMedCrossRef
22.
Jia H, Lubetkin EI, DeMichele K, Stark DS, Zack MM, Thompson WW (2018) Comparing the performance of 2 health utility measures in the medicare health outcome survey (HOS). Med Decis Mak 38:983–993CrossRef
23.
Nikolova S, Hulme C, West R, Pendleton N, Heaven A, Bower P et al (2020) Normative estimates and agreement between 2 measures of health-related quality of life in older people with frailty: findings from the community ageing research 75+ cohort. Value Health 23:1056–1062PubMedCrossRef
24.
Longworth L, Yang Y, Young T, Mulhern B, Hernandez Alava M, Mukuria C et al (2014) Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Technol Assess 18:1–224PubMedPubMedCentralCrossRef
25.
Brazier J, Ara R, Rowen D, Chevrou-Severac H (2017) A review of generic preference-based measures for use in cost-effectiveness models. PharmacoEconomics 35:21–31PubMedCrossRef
26.
Tsuchiya A, Dolan P (2005) The QALY model and individual preferences for health states and health profiles over time: a systematic review of the literature. Med Decis Mak 25:460–467CrossRef
27.
McNamee P (2007) What difference does it make? The calculation of QALY gains from health profiles using patient and general population values. Health Policy 84:321–331PubMedCrossRef
28.
Cleland J, Hutchinson C, Khadka J, Milte R, Ratcliffe J (2019) A review of the development and application of generic preference-based instruments with the older population. Appl Health Econ Health Policy 17:781–801PubMedCrossRef
29.
30.
Haehl E, Ruhle A, David H, Kalckreuth T, Sprave T, Stoian R et al (2020) Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly? Radiat Oncol 15:31PubMedPubMedCentralCrossRef
31.
Schad M, John J (2012) Towards a social discount rate for the economic evaluation of health technologies in Germany: an exploratory analysis. Eur J Health Econ 13:127–144PubMedCrossRef
32.
Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S et al (2015) Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess 19:1–503, v–viCrossRef
33.
Rühle A, Stromberger C, Haehl E, Senger C, David H, Stoian R et al (2020) Development and validation of a novel prognostic score for elderly head-and-neck cancer patients undergoing radiotherapy or chemoradiation. Radiother Oncol 154:276–282PubMedCrossRef
34.
Brentani A, de Castro G Jr., Federico MH (2011) Cost-effectiveness analysis of cisplatin-based chemoradiation to treat patients with unresectable, nonmetastatic head and neck cancer in Brazil. Head Neck 33:1199–1205PubMedCrossRef
35.
Sprave T, Zamboglou C, Verma V, Nicolay NH, Grosu AL, Lindenmeier J et al (2020) Characterization of health-related quality of life based on the EQ-5D-5L questionnaire in head-and-neck cancer patients undergoing modern radiotherapy. Expert Rev Pharmacoecon Outcomes Res 20:673–682PubMedCrossRef
36.
37.
Hinz A, Kohlmann T, Stobel-Richter Y, Zenger M, Brahler E (2014) The quality of life questionnaire EQ-5D-5L: psychometric properties and normative values for the general German population. Qual Life Res 23:443–447PubMedCrossRef
38.
Grochtdreis T, Dams J, Konig HH, Konnopka A (2019) Health-related quality of life measured with the EQ-5D-5L: estimation of normative index values based on a representative German population sample and value set. Eur J Health Econ 20:933–944PubMedCrossRef
39.
van de Poll-Franse LV, Mols F, Gundy CM, Creutzberg CL, Nout RA, Verdonck-de Leeuw IM et al (2011) Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. Eur J Cancer 47:667–675PubMedCrossRef
40.
Noel CW, Stephens RF, Su JS, Xu W, Krahn M, Monteiro E et al (2020) Mapping the EORTC QLQ-C30 and QLQ-H&N35, onto EQ-5D-5L and HUI‑3 indices in patients with head and neck cancer. Head Neck 42:2277–2286PubMedCrossRef
41.
42.
Konnopka A, Koenig HH (2017) The “no problems”-problem: an empirical analysis of ceiling effects on the EQ-5D 5L. Qual Life Res 26:2079–2084PubMedCrossRef
43.
You R, Liu J, Yang Z, Pan C, Ma Q, Luo N (2020) Comparing the performance of the EQ-5D-3 L and the EQ-5D-5 L in an elderly Chinese population. Health Qual Life Outcomes 18:97PubMedPubMedCentralCrossRef
44.
Bhadhuri A, Kind P, Salari P, Jungo KT, Boland B, Byrne S et al (2020) Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy. Health Qual Life Outcomes 18:317PubMedPubMedCentralCrossRef
45.
Thompson AJ, Turner AJ (2020) A comparison of the EQ-5D-3L and EQ-5D-5L. PharmacoEconomics 38:575–591PubMedCrossRef
46.
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20:1727–1736PubMedPubMedCentralCrossRef
47.
Pickard AS, De Leon MC, Kohlmann T, Cella D, Rosenbloom S (2007) Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Med Care 45:259–263PubMedCrossRef
48.
Leidl R, Reitmeir P (2011) A value set for the EQ-5D based on experienced health states: development and testing for the German population. PharmacoEconomics 29:521–534PubMedCrossRef
49.
Makai P, Brouwer WB, Koopmanschap MA, Stolk EA, Nieboer AP (2014) Quality of life instruments for economic evaluations in health and social care for older people: a systematic review. Soc Sci Med 102:83–93PubMedCrossRef
50.
Wyrwich KW, Norquist JM, Lenderking WR, Acaster S, Industry Advisory Committee of International Society for Quality of Life R (2013) Methods for interpreting change over time in patient-reported outcome measures. Qual Life Res 22:475–483PubMedCrossRef
51.
Garau M, Shah KK, Mason AR, Wang Q, Towse A, Drummond MF (2011) Using QALYs in cancer: a review of the methodological limitations. PharmacoEconomics 29:673–685PubMedCrossRef
Metadata
Title
Cost effectiveness and health-related quality of life of chemoradiotherapy versus radiation therapy alone in elderly head and neck cancer patients
Authors
Tanja Sprave, M.D., M.B.A.
Vivek Verma, M.D.
Alexander Fabian, M.D., M.B.A.
Alexander Rühle, M.D.
Dimos Baltas, Ph.D.
Anca-Ligia Grosu, M.D.
Nils H. Nicolay, M.D., Ph.D.
Publication date
14-07-2022
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 11/2022
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-022-01975-6

Other articles of this Issue 11/2022

Strahlentherapie und Onkologie 11/2022 Go to the issue

Literatur kommentiert

ORATOR2-Studie – randomisierter Vergleich einer primären Operation oder primären Strahlentherapie bei HPV-positivem Oropharynxkarzinom im Kontext einer Therapiedeeskalation

Original Article

Impact of dosimetric factors on long-term percutaneous enteral gastrostomy (PEG) tube dependence in head and neck cancer patients after (chemo)radiotherapy—results from a prospective randomized trial

Original Article

Radio(chemo)therapy in anaplastic thyroid cancer—high locoregional but low distant control rates—a monocentric analysis of a tertiary referral center

Original Article

Selective local postoperative radiotherapy for T3–T4 N0 laryngeal cancer

Original Article

Impact of a ketogenic diet intervention during radiotherapy on body composition: V. Final results of the KETOCOMP study for head and neck cancer patients

Review Article

DEGRO practical guideline for central nervous system radiation necrosis part 2: treatment